Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

Drug Name

Olumiant® (baricitinib)

Company / Licensee

Incyte / Eli Lilly

Therapy Class

JAK inhibitor

Product Description

JAK1 and JAK2 inhibitor

Current Indication

Rheumatoid arthritis

Market Sector

Rheumatology

Current Status

Approved in the US, Japan and Europe
Expand
Close
Close
Close

Go Top